Adam Walsh
Stock Analyst at Roth Capital
(2.72)
# 2,351
Out of 5,182 analysts
18
Total ratings
62.5%
Success rate
19.16%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Adam Walsh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EQ Equillium | Reiterates: Buy | $12 | $2.04 | +488.24% | 2 | Apr 17, 2026 | |
| INSM Insmed | Reiterates: Buy | $212 | $135.98 | +55.91% | 2 | Apr 17, 2026 | |
| APLS Apellis Pharmaceuticals | Initiates: Buy | $31 | $40.95 | -24.30% | 1 | Mar 13, 2026 | |
| VTVT vTv Therapeutics | Initiates: Buy | $58 | $29.40 | +97.28% | 1 | Jan 23, 2026 | |
| ASND Ascendis Pharma | Maintains: Buy | $146 → $171 | $226.66 | -24.56% | 3 | Apr 20, 2020 | |
| GLPG Galapagos NV | Maintains: Buy | $121 → $188 | $28.55 | +558.49% | 4 | Jul 15, 2019 | |
| CORT Corcept Therapeutics | Downgrades: Hold | n/a | $46.22 | - | 4 | May 31, 2018 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $74 → $77 | $23.99 | +220.97% | 1 | Apr 18, 2018 |
Equillium
Apr 17, 2026
Reiterates: Buy
Price Target: $12
Current: $2.04
Upside: +488.24%
Insmed
Apr 17, 2026
Reiterates: Buy
Price Target: $212
Current: $135.98
Upside: +55.91%
Apellis Pharmaceuticals
Mar 13, 2026
Initiates: Buy
Price Target: $31
Current: $40.95
Upside: -24.30%
vTv Therapeutics
Jan 23, 2026
Initiates: Buy
Price Target: $58
Current: $29.40
Upside: +97.28%
Ascendis Pharma
Apr 20, 2020
Maintains: Buy
Price Target: $146 → $171
Current: $226.66
Upside: -24.56%
Galapagos NV
Jul 15, 2019
Maintains: Buy
Price Target: $121 → $188
Current: $28.55
Upside: +558.49%
Corcept Therapeutics
May 31, 2018
Downgrades: Hold
Price Target: n/a
Current: $46.22
Upside: -
Ultragenyx Pharmaceutical
Apr 18, 2018
Maintains: Buy
Price Target: $74 → $77
Current: $23.99
Upside: +220.97%